Chris Costas
Infectious Disease · Chicago, ILNPI 1992732630
Payments from drug & device makers
Across 301 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- Johnson & Johnson$631
- Merck$282
- Napo Pharmaceuticals Inc$241
- Janssen Products, LP$199
- plus $382 from 9 others
What the payments were for
- Speaking & faculty fees$361%
- Food & beverage$4,60495%
- Education$2124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 125 | $1,783 |
| Gilead | 82 | $1,334 |
| Johnson & Johnson | 40 | $631 |
| Merck | 15 | $282 |
| Napo Pharmaceuticals Inc | 16 | $241 |
| Janssen Products, LP | 2 | $199 |
| AbbVie(2 entities) | 5 | $123 |
| EMD Serono, Inc. | 2 | $48 |
| Melinta Therapeutics, LLC | 2 | $46 |
| Novo Nordisk | 2 | $41 |
| Dynavax Technologies Corporation | 4 | $37 |
| Pfizer | 2 | $32 |
| Mayne Pharma Commercial LLC | 2 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Smith+Nephew | 1 | $15 |
How this compares
$4,852 in reported general payments places this provider in the 80th percentile of 368 infectious disease providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $51,324 |
| DescovyEmtricitabine/Tenofov Alafenam | 16 | $40,672 |
| TivicayDolutegravir Sodium | 11 | $28,624 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $9,702 |
| Gabapentin | 15 | $481 |
| Losartan Potassium | 12 | $151 |
| Spironolactone | 13 | $127 |
| Atorvastatin Calcium | 13 | $90 |
| Medroxyprogesterone Acetate | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,334 | $91,99628 claims |
| Viiv Healthcare CompanyTivicay | $1,783 | $28,62411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 368 infectious disease providers in Illinois.
Other infectious disease in Chicago
- Kathleen MullaneChicago$4.4M
- Gregory HuhnChicago$3M
- Catherine CreticosChicago$1.7M
- Babafemi TaiwoChicago$1.4M
- Shivanjali ShankaranChicago$1.1M
- Frank PalellaChicago$987K
- Kamaljit SinghChicago$971K
- Richard NovakChicago$960K
- Renslow ShererChicago$821K
- Mariam AzizChicago$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.